Delta Financial Advisors LLC boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 59.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,869 shares of the biopharmaceutical company’s stock after buying an additional 11,509 shares during the quarter. Delta Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,982,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Bristol-Myers Squibb by 6.7% in the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after buying an additional 7,178,698 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in Bristol-Myers Squibb by 42.5% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,527,341 shares of the biopharmaceutical company’s stock valued at $671,013,000 after buying an additional 3,140,646 shares during the last quarter. California Public Employees Retirement System grew its stake in Bristol-Myers Squibb by 24.3% in the 4th quarter. California Public Employees Retirement System now owns 7,827,076 shares of the biopharmaceutical company’s stock valued at $502,420,000 after buying an additional 1,532,029 shares during the last quarter. Swiss National Bank grew its stake in Bristol-Myers Squibb by 36.2% in the 4th quarter. Swiss National Bank now owns 7,494,688 shares of the biopharmaceutical company’s stock valued at $481,084,000 after buying an additional 1,992,824 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in Bristol-Myers Squibb by 38.1% in the 4th quarter. New York State Common Retirement Fund now owns 5,495,947 shares of the biopharmaceutical company’s stock valued at $352,785,000 after buying an additional 1,515,047 shares during the last quarter. Institutional investors own 84.33% of the company’s stock.

BMY has been the topic of a number of research analyst reports. Gabelli initiated coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, November 27th. They issued a “buy” rating on the stock. Wolfe Research set a $66.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, November 1st. William Blair reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Friday, December 13th. Mizuho initiated coverage on shares of Bristol-Myers Squibb in a research report on Monday, November 25th. They issued a “buy” rating on the stock. Finally, ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $61.69.

Shares of Bristol-Myers Squibb stock opened at $66.55 on Friday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. The firm’s 50-day simple moving average is $64.96 and its 200-day simple moving average is $55.92. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $68.34. The firm has a market cap of $109.02 billion, a P/E ratio of 30.39, a price-to-earnings-growth ratio of 1.29 and a beta of 0.76.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.34. Bristol-Myers Squibb had a net margin of 13.15% and a return on equity of 48.97%. The business had revenue of $7.95 billion for the quarter, compared to analyst estimates of $6.20 billion. During the same period in the previous year, the business earned $0.94 EPS. The firm’s revenue was up 33.0% on a year-over-year basis. On average, equities analysts forecast that Bristol-Myers Squibb Co will post 6.16 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a dividend of $0.45 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 annualized dividend and a yield of 2.70%. The ex-dividend date was Thursday, January 2nd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 38.38%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: How is the LIBOR rate calculated?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.